Revenue ($USD) : $747,718,000
R&D spend : $169,667,000
Employees : 2,400
Fiscal year end : 12/31/2023
CEO : John Sheridan

www.tandemdiabetes.com

Tandem Diabetes Care develops automated insulin delivery systems such as its flagship t:slim X2. It launched the Mobi miniature, durable pump in February 2024. Tandem completed significant CGM integrations in 2024 and plans to bring the Sigi patch pump acquired from AMF Medical to market. Tandem continues to register significant growth, projecting sales of nearly $900 million in 2024. –SW